Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 9, 1070-1083, September 2007; doi:10.1634/theoncologist.12-9-1070
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Superfin, D.
Right arrow Articles by Davies, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Superfin, D.
Right arrow Articles by Davies, A. M.

Clinical Pharmacology

Commentary: Oncologic Drugs in Patients with Organ Dysfunction: A Summary

Diana Superfin, Andrea A. Iannucci, Angela M. Davies

University of California Davis Cancer Center, Sacramento, California, USA

Key Words. Hepatic • Renal • Dysfunction • Chemotherapy • Cancer

Correspondence: Angela M. Davies, M.D., F.R.C.P.C., Hematology/Oncology, University of California Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, California 95817, USA. Telephone: 916-734-3771; Fax: 916-734-7946; e-mail: angela.davies{at}ucdmc.ucdavis.edu

Disclosure: A.M.D. has acted as a consultant for Bristol-Myers Squibb, Allos Therapeutics, CTI Therapeutics, Genentech, Millennium, and Lilly, and has received support from Genentech and Aventis.

There are few prospective data regarding the pharmacokinetics and clinical toxicity of commonly used chemotherapeutics in cancer patients with organ dysfunction. Although increasing numbers of studies are investigating newer chemotherapeutics in patients with liver or kidney dysfunction, most guidelines for dosing, especially for established agents, remain empiric. This review describes the available data (both prospective and case study) evaluating the impact of renal and hepatic dysfunction on toxicity and dosing of commonly used chemotherapeutics and provides a practical summary for their use in this setting.




This article has been cited by other articles:


Home page
 The OncologistHome page
T. E. Hutson, R. A. Figlin, J. G. Kuhn, and R. J. Motzer
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Oncologist, October 1, 2008; 13(10): 1084 - 1096.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement